BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months
RARE upcoming catalysts
Ultragenyx Pharmaceutical Inc: 1 upcoming industry Phase 2/3 trial readout(s) in the next 90 days (1 Phase 3), 0 upcoming FDA decision event(s), and in the last 12 months 3 readout(s) and 3 FDA event(s). Subscribe to RARE (.ics).
Drugs: GTX-102, setrusumab
Upcoming FDA decision events
| Date | Event | Status | Company | Drug | Source |
|---|---|---|---|---|---|
| No upcoming PDUFA date or AdCom found. | |||||
Upcoming trial readouts
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2027-01 est. | P3 | Ultragenyx Pharmaceutical Inc RARE | NCT06636071 Setrusumab in Pediatric Japanese Subjects With Osteogenesis Imperfecta | Osteogenesis Imperfecta | active not recruiting | 6 |
FDA decision events, last 12 months
| Date | Event | Status | Company | Drug | Source |
|---|---|---|---|---|---|
| 2026-09-19 | PDUFA date (company-disclosed) | date passed | Ultragenyx Pharmaceutical Inc. RARE | apazunersen | PDUFA September 19, 2026 - Ultragenyx Pharmaceutical Inc. (apazunersen) |
| 2026-08-23 | PDUFA date (company-disclosed) | date passed | Ultragenyx Pharmaceutical Inc. RARE | rebisufligene | PDUFA August 23, 2026 - Ultragenyx Pharmaceutical Inc. (rebisufligene) |
| 2026-07-01 (half) | PDUFA date (company-disclosed) | date passed | Ultragenyx Pharmaceutical Inc. RARE | PDUFA second half of 2026 - Ultragenyx Pharmaceutical Inc. |
Trial readouts, last 12 months
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2026-10-30 | P2 | Ultragenyx Pharmaceutical Inc RARE | NCT07157254 A Safety and Efficacy Study of GTX-102 in Subjects With Deletion- or Nondeletion-type Angelman Syndrome (AS) | Angelman Syndrome | terminated | 55 |
| 2026-10-30 | P3 | Ultragenyx Pharmaceutical Inc RARE | NCT06415344 Long-term Extension of GTX-102 in Angelman Syndrome | Angelman Syndrome | terminated | 66 |
| 2026-07-10 | P3 | Ultragenyx Pharmaceutical Inc RARE | NCT06617429 Phase 3 Efficacy and Safety Study of GTX-102 in Pediatric Subjects With Angelman Syndrome (AS) | Angelman Syndrome | terminated | 129 |
Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line
results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are
company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA
(openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score.
Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP
readout_calendar / fda_decisions. Not investment advice.